Preliminary studies on coronavirus vaccines have produced promising results. I'm still a believer in their technology. Check out my previous NVAX posts and/or the first one. They have a promising technology that could revolutionize the vaccine industry. We (humanity) are already very behind in how we produce vaccines AKA using chicken eggs. So Novavax will...
This week won't be complete with some volatility because of unemployement rates,vaccine news and also elections. SPY has gaps to fill on upside and also downside. Down it has to go to 320.20,up to 325.11. 321.28 seems to be where things are bouncing PM so that would be a good level to watch. If we go bellow then 320.20 will be for sure there as well to fill the...
Stocks did not get too much of a boost from the FOMC event yesterday, unlike other assets. Right now, the S&P is still hovering between the range we have been watching for a while now, between 3200, a technical, psychological, and Fibonacci level, and 3280, a relative high and Fibonacci level. However, Ghostsquawk's risk sentiment analysis is picking up some...
Some great vaccine news as US prepares to vaccinate the American population with 100M doses worth up to 2Billion USD and supplied by Pfizer and BioNtech!. The resistance line that PFE was under represents a long term hard resistance since 2018. PFE might go a lot higher now, perhaps as high as Moderna.
Hello traders! Good news from Novavax! The chances of approval for flu vaccine candidate NanoFlu seems actually quite good! Moreover, if we look at the chart, we can see that the price is on a strong uptrend that doesn't seem to want to stop. The bullish momentum is still strong! Remember to put a stop loss in order to secure your capital! Not a financial...
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency...
Yet another potentially profitable play regarding the Covid-19 pandemic is $MRNA, A pharmaceutical company that is currently entering its 3rd phase of a corona Vaccine. While this play depends largely on its vaccine success over the rest of the month this could be an extremely lucrative play. It has been in a consolidation zone for the past few weeks, a Good buy...
I still believe NVAX has a lot of potential and I'll say it again. My idea is clear that its NanoParticle and Matrix-M Adjuvant tech makes it a prime candidate for a COVID-19 vaccines. Even if it doesn't make it first (or ever), it still has major potential for the seasonal influenza (w/ NanoFlu) and its Respiratory Syncytial Virus (RSV) vaccine. Check out my...
Finally, coronavirus vaccines and treatments should serve as a tailwind for the health care industry as a whole. Hardy is projecting mid-single-digit earnings growth over the long term, including 9% earnings per share growth in fiscal 2020. CFRA has a "strong-buy" rating and a $109 price target for ABC stock.
Just re-iterating my previous assertion (guess) that NVAX is on course for massive gains in the long-term. Doesn't mean it's a great company but this pandemic has initiated a similar pattern in the past. They have several great developments in the works: NanoFlu, RSV F, and a COVID-19 vaccine candidate. See my previous posts especially the related one. This is...
This company has not done anything noteworthy for the last few years. They were able to get funding from the European International Bank to work on COVID related solutions released in 3 tranches. The likely outcome is they will not make enough progress to unlock the future tranches. Seems to me like they are just grabbing the handout and will resume their...
First off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, let me get into my insights. There was rumors that AstraZeneca wanted to merge w/ Gilead. However, it looks like this may not happen. Until, the books are closed don't get your hopes up, but invest as if you expect...